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Introduction 
Fragile sites have long been identified by 
cytogeneticists as specific chromosomal regions that 
exhibit an increased frequency of gaps or breaks when 
cells are exposed to a DNA replication stress in vitro 
(Sutherland, 1977). Fragile sites have been classified as 
rare or common on the basis of their expression 
frequency within a general population (Schwartz et al., 
2006). Rare fragile sites (RFSs) are identifiable in less 
than 5% of the general population, whereas common 
fragile sites (CFSs) are intrinsic chromosomal regions 
that are present in all individuals. Most of the CFSs are 
induced by aphidicolin, whereas others are induced by 
bromodeoxyuridine or 5-azacytidine. Since the 
discovery of CFSs, it has been observed that many of 
them appear to coincide with aberrant chromosomal 
regions in various cancers, which has driven numerous 
studies to isolate genes at CFSs to better understand the 
molecular basis of their fragility and their implications 
in the mechanisms of tumorigenesis. To date, as many 
as 120 CFSs and RFSs have been identified in the 
human genome (Lukusa and Fryns, 2008). CFSs are a 
very broad topic that encompasses various fields 
including cytogenetics, epigenomics, and oncology. In 
this review, we will first overview the molecular 
characteristics of CFSs, their implications in 
tumorigenesis, and several representative genes located 
at CFSs. We will then focus on the molecular basis of 
the mechanisms underlying fragility and the repair 
processes of double-strand breaks involving CFSs 
based on the analyses of breakpoints. The findings 
indicate that chromosomal instability associated with 
CFSs plays an important role, not only in somatic 
rearrangements associated with cancers, but also in 
germline rearrangements leading to human hereditary 
diseases. 
I. Molecular characteristics of CFSs 
Several CFSs have been cloned and characterized at the 
molecular level using various methods. Although the 
mechanisms underlying CFS breakage are still unclear, 
several factors that may contribute to instability at 
CFSs have been suggested, including relatively AT-
rich regions (Lukusa and Fryns, 2008), late-replicating 
regions (Handt et al., 2000; Hellman et al., 2000; Le 
Beau et al., 1998b; Palumbo et al., 2010), high-
flexibility peaks (Mishmar et al., 1998; Zlotorynski et 
al., 2003), regions rich in nuclear matrix attachment 
regions (Mishmar et al., 1998; Morelli et al., 2002; 
Wang et al., 1997), and regions located at the interface 
of G- and R-bands (El Achkar et al., 2005). Notably, 
CFSs do not show any repeat motifs such as expanded 
trinucleotide or minisatellite repeats that could 
predispose them to fragility, as have been demonstrated 
in RFSs (Schwartz et al., 2006). A recent study on the 
replication dynamics of FRA3B in human lymphocytes 
has shown that, rather than breakage being due to 
replication stalling, the fragility of FRA3B depends on 
the paucity of initiation events. Even more surprisingly, 
the fragility of FRA3B is specific to cells showing this 
particular initiation pattern (Letessier et al., 2011). 
These findings suggest that the fragility of CFSs does 
not depend on nucleotide sequences alone, but that 
CFSs are epigenetically defined chromosomal loci that 
correspond to the initiation-sparse regions in a given 
cell type. For historical reasons, CFSs have usually 
been mapped in lymphocytes, and have been 
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considered to be intrinsic characteristics of the 
chromosomes that are present regardless of the cell 
type. Therefore, the contribution of CFSs to 
chromosomal rearrangements should be thoroughly 
reassessed in cells derived from various tissue types. 
II. Implications of CFSs 
Since the discovery of CFSs, they have been 
increasingly recognized to be preferential sites for the 
integration of exogenous oncogenic DNA viruses 
(Popescu et al., 1990) and hotspots for chromosomal 
rearrangements (deletions, duplications, amplifications, 
or translocations) in various cancers (Lukusa and 
Fryns, 2008). Hence, it was hypothesized that CFSs can 
facilitate recombination events that result in clonally 
expanded cancer cell populations with specific 
chromosome alterations in specific cancer types. An 
extension of this hypothesis is that the clonal expansion 
is driven by damage to genes at CFSs and the 
consequent loss of expression these genes (Drusco et 
al., 2011). A counter argument is that, because of the 
frequent deletions within the CFSs, the loss of any 
associated gene expression is an unselected passenger 
event and does not drive the expansive growth of 
cancer cells (Bignell et al., 2010; Le Beau et al., 
1998a). Although this issue should be considered on an 
individual CFS basis, a considerable amount of data 
supporting the tumor suppressor potential of FHIT at 
FRA3B, WWOX at FRA16D, and PARK2 at FRA6E 
has been accumulated. The biological effect of the loss 
of function of these genes has been evaluated from 
various view points. 
III. Contributions of CFS genes to 
oncogenesis 
(1). FHIT at FRA3B 
FHIT (MIM 601153), located at 3p14.2, spans more 
than 1.5 Mb encompassing ten exons encoding an open 
reading frame of 444 bp that is translated into a 16.9 
kDa protein (Ohta et al., 1996). FHIT is a histidine 
triad protein, which represents a small family of 
nucleotide-binding and hydrolyzing proteins (Hassan et 
al., 2010). Although the exact biological function of 
FHIT still remains unclear, it has received the attention 
of cancer biologists because of its potential role as a 
tumor suppressor gene. The injection of chromosome 
3p14-p12 encompassing FHIT into a renal carcinoma 
cell line resulted in the partial suppression of tumor 
growth in nude mice (Sanchez et al., 1994). There have 
been many studies demonstrating that the 
overexpression of FHIT significantly inhibited cell 
growth in various FHIT-deficient cancer cell lines (Ji et 
al., 1999; Sard et al., 1999). Although spontaneous 
phenotypes are not observed in a Fhit-deficient mouse 
model, they showed vulnerability to high-dose-
radiation-induced tumor development (Yu et al., 2009) 
and chemically induced bladder tumor development 
(Vecchione et al., 2004). Fhit-deficient mice were also 
used to produce mouse models deficient in multiple 
tumor suppressors and upregulated oncogenes, Vhl 
(Zanesi et al., 2005) and Her2 (Bianchi et al., 2007), 
respectively. These studies showed the tumorigenic 
effects of FHIT deficiency itself and of the 
simultaneous deregulation of another cancer-associated 
gene owing to FHIT deficiency. 
(2). WWOX at FRA16D 
WWOX (MIM 605131), located at 16q23, spans more 
than 1.1 Mb encompassing nine exons encoding an 
open reading frame of 1,245 bp that is translated into a 
46.7 kDa protein. The WWOX protein includes two 
WW domains and a short-chain 
dehydrogenase/reductase domain homologous to 17β-
hydroxysterol reductase, which may be involved in sex-
steroid metabolism (Aqeilan and Croce, 2007). 
WWOX overexpression induces the inhibition of 
tumorigenicity of breast cancer cells in nude mice 
(Bednarek et al., 2001). Several lines of evidence 
indicate that the overexpression of WWOX significantly 
inhibits cell growth in various WWOX-deficient cancer 
cell lines (Fabbri et al., 2005; Iliopoulos et al., 2007; 
Kuroki et al., 2004; Qin et al., 2006). Although Wwox 
null mice exhibit a metabolic disorder characterized by 
hypoglycemia and hypocalcemia, and die at 3-4 weeks 
of age, the spontaneous occurrence of osteosarcomas in 
Wwox null mice and lung papillary carcinoma in Wwox 
heterozygous mice were reported (Aqeilan et al., 
2007b). In addition, Wwox heterozygous mice showed 
vulnerability to chemically induced lung tumors and 
lymphomas (Aqeilan et al., 2007a; Aqeilan et al., 
2007b). 
(3). PARK2 at FRA6E 
PARK2 (MIM 602544), located at 6q26, spans 
approximately 1.4 Mb encompassing twelve exons 
encoding an open reading frame of 1,398 bp that is 
translated into a 51.6 kDa protein. The PARK2 protein 
is a ubiquitously expressed ubiquitin E3 ligase that is 
considered to target specific proteins for proteasomal 
degradation (Imai et al., 2000), and its mutations are 
responsible for autosomal recessive juvenile 
Parkinsonism (AR-JP [MIM 600116]) (Kitada et al., 
1998). As FHIT and WWOX have been well established 
to be associated with tumor suppression genes, PARK2 
was also considered to be one of the tumor suppressor 
genes.Indeed PARK2 overexpression induces the 
inhibition of tumorigenicity of lung cancer cells in nude 
mice (Picchio et al., 2004). PARK2 null mice do not 
develop any tumor spontaneously, but interbreeding of 
Park2 heterozygous mice with Apc mutant mice results 
in the acceleration of intestinal adenoma development 
and increases polyp multiplicity (Poulogiannis et al., 
2010). 
IV. Germline and somatic mutations 
in PARK2 
As mentioned above, mutations of PARK2 are 
responsible for AR-JP. Among various causative 
germline mutations in PARK2, gross deletions account 
for 50 to 60% of these mutations (Periquet et al., 2001) 
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with the deletion hotspots clustering in exons 3 and 4 
(Hedrich et al., 2004). PARK2 is also frequently 
targeted by deletions in various cancer cells (Denison et 
al., 2003b; Toma et al., 2008; Veeriah et al., 2010; Yin 
et al., 2009). Although it has not drawn much attention, 
the frequent occurrence of gross rearrangements in the 
genomic regions corresponding to CFSs in patients 
with AR-JP suggests that a common basis underlies the 
frequent occurrence of rearrangements in both germ 
cell and somatic cell lines. To explore why these 
particular genomic regions are prone to rearrangements 
in germ cells and cancer cells, it is essential to 
determine the precise positions of the regions with 
breakpoint clusters, and to analyze the junction 
sequence signatures in detail. The determination of 
junction sequences, however, has been extremely 
laborious by conventional methods such as the 
polymerase chain reaction (PCR)-based genome-
walking method, particularly in the case of large 
rearrangements. To date, only a few breakpoints 
involving PARK2 have been determined at the 
nucleotide level in either germ cell or somatic cell 
mutations (Asakawa et al., 2009; Clarimon et al., 2005; 
Hedrich et al., 2004). To efficiently determine 
deletion/duplication breakpoints at the nucleotide level, 
we have recently applied a custom-designed high-
density array comparative genomic hybridization (array 
CGH) system, which enabled us to determine 
approximately 300 breakpoints in patients with AR-JP 
as well as in cancer cell lines (Mitsui et al., 2010). The 
results of our recent study will be described below in 
detail. 
(1). Rearrangement hot spots 
Unrelated 206 patients with AR-JP were analyzed and 
268 exonic rearrangements (243 deletions and 25 
duplications) and 5 intronic deletions were detected. 
The nucleotide sequences of the 252 breakpoint 
junctions were determined, which included 235 
deletions and 17 duplications. It was found that 140 of 
the 252 breakpoints in PARK2 in patients with AR-JP 
were distinct, indicating that multiple independent 
rearrangements frequently occurred in PARK2. For 
comparison of the  
breakpoints in the germline mutations in patients with 
AR-JP, we then conducted similar array CGH analyses 
of PARK2 in 125 cancer-derived cell lines and 
identified 42 rearrangements (39 deletions and 3 
duplications) in 28 of the cancer cell lines (22.4%). 
Note that the frequencies of rearrangements in PARK2 
in cancer cell lines were quite high, supporting the 
instability of the CFS-associated locus in cancer cell 
lines. The nucleotide sequences of the 41 breakpoint 
junctions, including 39 deletions and 2 duplications 
were determined. Because 10 deletions and 2 
duplications were found among multiple cancer cell 
lines, 32 independent breakpoints (31 deletions and 1 
duplication) were determined. Among 32 independent 
breakpoints, 2 (1 deletion and 1 duplication) were also 
found in patients with AR-JP, raising the possibility 
that they were derived from germ cell lines or that the 
identical rearrangements of germ cell lines 
independently occurred in somatic cell lines. 
Intriguingly, in one cancer cell line, 6 independent 
deletions were observed in PARK2 simultaneously. 
We found that the breakpoints were obviously clustered 
at specific genomic regions in PARK2 and the regions 
with breakpoint clusters in patients with AR-JP closely 
coincided with the previously reported region in 
FRA6E prone to DNA double-strand breaks, which has 
been referred to as the center of FRA6E (Denison et al., 
2003a) (Figure 1). The center of the breakpoint 
distribution in PARK2 may be similar in germ cell lines 
and cancer cell lines, but the variance of the 
distribution may be larger in cancer cell lines than that 
in germ cell lines. One possible explanation for the 
difference is that the sample selections for patients with 
AR-JP biased the breakpoint distributions and the 
cancer cell lines tended to generate larger 
rearrangements in that locus owing to increased 
genomic instability. The Database of Genomic Variants 
(accessed in March 2010) (Iafrate et al., 2004) included 
48 copy number variations (CNVs: more than 1 kb in 
length) in the regions in PARK2. The distributions of 
these breakpoints in PARK2 showed similarities with 
those observed in patients with AR-JP (Figure 1). 
(2). Junction sequences 
On the basis of the sequences flanking the breakpoints 
of PARK2, junction sequence signatures were analyzed 
and then classified into three groups: 1. junctions with 
extended homologies, 2. junctions with 
microhomologies, and 3. junctions without extended 
homologies or microhomologies (Figure 2). We refer to 
short stretches of identical sequences (≤ 8 bp) at 
breakpoint junctions as microhomologies. A search for 
extended homologies revealed that 7 of the 162 
junctions (4.3%) in patients with AR-JP and 1 of the 32 
junctions (3.1%) in cancer cell lines had extended 
homologies, all of which were embedded in the same 
repetitive sequences (Alu/Alu).  
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Figure 1. Cumulative frequency distributions and histograms of breakpoint positions in PARK2. 
A. Cumulative frequency distributions of breakpoint positions in PARK2 in patients with AR-JP, cancer cell lines, and control subjects. 
The horizontal axis represents the nucleotide positions of breakpoints. The vertical axis represents the cumulative frequencies of 
breakpoints. The upstream breakpoints are shown in white, while the downstream breakpoints are shown in black. Physical maps of 
PARK2 along with schematic representations of the center of FRA6E are shown above. 
B. Histograms of breakpoint positions in PARK2 in AR-JP patients and cancer cell lines. The horizontal axis represents nucleotide 
positions and the vertical axis represents the number of breakpoints. The numbers of the positions of the upstream (toward the 
transcriptional initiation site) breakpoints are shown in white, while those of the downstream breakpoints are shown in black. Physical 
maps of PARK2 along with schematic representations of the center of FRA6E are shown above. 
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The majority of the junctions were frequently 
associated with microhomologies; 97 of the 162 
junctions (59.9%) in patients with AR-JP and 19 of the 
32 junctions (59.4%) in cancer cell lines had 
microhomologies. Regarding the junctions without 
extended homologies or microhomologies, it was 
revealed that 58 of the 162 junctions (35.8%) in 
patients with AR-JP and 12 of the 32 junctions (37.5%) 
in cancer cell lines were without extended homologies 
or identical sequences. Among these, 51 of the 162 
junctions in patients with AR-JP and 8 of the 32 
junctionsin cancer cell lines had inserted sequences. 
We found that 4 junctions in patients with AR-JP and 2 
junctions in cancer cell lines had inserted sequences of 
more than 19 bp, whose origins were searched for using 
the BLAST program. It was revealed that 2 inserted 
sequences in cancer cell lines originated from repetitive 
sequences (1 Alu and 1 THE1B). The origins of the 
other inserted sequences remained undetermined. 
Notably, there are similarly high frequencies of 
microhomologies in germ cell and cancer cell lines, 
which support the notion that a common mechanism 
underlies the generation of rearrangements in germ cell 
and cancer cell lines. Consistent with our findings, 
microhomologies at junctions have recently been 
observed in the rearrangements in human culture cells 
experimentally induced using aphidicolin (Arlt et al., 
2009). In contrast, rearrangements that can be 
explained by the homology-dependent nonallelic 
homologous recombination (NAHR) are relatively rare, 
because there are only a limited number of 
rearrangements whose junctions show extended 
homologies. Considering the observation that multiple 
independent rearrangements frequently occurred in 
PARK2 in germ cells, it is in striking contrast to other 
common genomic disorders such as Charcot-Marie-
Tooth disease type 1A (Lupski, 1998) or Smith-
Magenis syndrome (Chen et al., 1997) whose recurrent 
mutations are characterized by homologous 
recombination and unequal crossing over between the 
flanking repeat elements. 
Various mechanisms of rearrangement processes that 
can result in microhomologies at junctions have been 
proposed, which include nonhomologous end joining 
(NHEJ), microhomology-mediated end joining 
(MMEJ), microhomology-mediated break-induced 
replication (MMBIR), and/or fork stalling and template 
switching (FoSTeS) (Figure 2). In eukaryotes, NHEJ is 
the major repair pathway of DNA double-strand breaks, 
and functions by ligating their two ends together 
(Lieber, 2008). It has the potential to ligate any type of 
double-strand break end without the requirement for an 
extended homology. Even when starting with two 
identical DNA ends, NHEJ is a highly flexible process 
accounting for the diverse breakpoint junctions, with 
some ends showing short microhomologies (usually 1 
to 4 bp) and some ends showing inserted sequences 
without microhomologies (Lieber, 2008). In addition, it 
was shown that replication stress leads to the focus 
formation of key components of the NHEJ pathway 
(Rad51 and DNA-PKcs) colocalized with markers of 
DNA double-strand breaks (MDC1 and gamma 
H2AX), and the down-regulation of the component of 
the NHEJ pathway (Rad 51, DNA-PKcs, or DNA 
ligase 4) leads to a significant increase in gaps and 
breaks at CFSs (Schwartz et al., 2005). MMEJ is 
another distinctive pathway of end-joining repair, 
which requiresmicrohomologies of terminal ends in 
contrast to NHEJ. High frequencies of 
microhomologies at junctions observed in this study 
would favor the involvement of MMEJ at CFSs. 
Recently, the MMBIR and/or FoSTeS model with 
emphasis on replication fork collapse and/or stalling 
has also been proposed to explain the origin of 
rearrangements on the basis of the findings of complex 
rearrangements and junction sequences showing 
microhomologies of 2 to 5 bp (Zhang et al., 2009).. 
Because replication mechanisms at CFSs have been 
implicated to underlie the rearrangements involving 
CFSs, MMBIR/FoSTeS deserves serious consideration 
as a possible mechanism underlying the rearrangements 
at CFSs 
(3). Genomic and epigenomic characteristics 
On the basis of a recent study of a replication timing 
map (Woodfine et al., 2005), it was found that one of 
the latest-replication regions coincided with the regions 
with breakpoint clusters in PARK2. To investigate 
flexibility peaks, the regions with breakpoint clusters 
and the neighboring regions were analyzed. Although 
flexibility peaks in the breakpoint clustering regions in 
PARK2 were not overrepresented compared with those 
in their neighboring regions, there were regions with 
high AT content (AT repeats) near the regions with 
breakpoint, and the highest-flexibility peaks flanked the 
regions with breakpoint clusters. On a high-resolution 
map of the interaction sites of the human genome with 
nuclear lamina components, it was revealed that 
PARK2 was embedded in large lamina associated 
domains (LADs) (Guelen et al., 2008). This prompted 
us to investigate the relationships of LADs with other 
CFS genes including FHIT, WWOX, DMD, GRID2, 
LARGE, CTNNA3, NBEA, and CNTNAP2. Intriguingly, 
all the CFS genes were embedded in large LADs 
spanning several Mb. Using the deCODE map, the 
meiotic recombination rate of the breakpoint clustering 
regions in PARK2 was found to be high, as previously 
reported (Asakawa et al., 2009). 
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Figure 2. Schematic representations of rearrangement mechanisms. 
A. Junctions with extended homologies are usually explained by nonallelic homologous recombination (NAHR), a form of homologous 
recombination that occurs between two lengths of DNA sequences (red and pink regions) that have high sequence homologies, but are 
not alleles. 
B. Junctions with microhomologies can be explained by nonhomologous end joining (NHEJ), microhomology-mediated end joining 
(MMEJ), or microhomology-mediated break-induced replication/fork stalling and template switching (MMBIR/FoSTeS). Schematic 
representations of MMEJ and MMBIR/FoSTeS are shown. 
C. Junctions without extended homologies or microhomologies can be explained by NHEJ. 
 
 (4). Involvement of CFSs with rearrangements in 
germlines leading to human diseases 
Although several lines of evidence have demonstrated 
that somatic rearrangements that occur within CFSs are 
associated with cancer development, CFSs have rarely 
drawn attention as genomic structures associated with 
germline rearrangements. Our study suggests that 
chromosomal instability associated with CFSs plays an 
important role in gross deletions and duplications in 
germ cell lines leading to human diseases. Supporting 
this hypothesis, we also found that, similarly to 
PARK2, DMD (MIM 300377), which is embedded in a 
CFS (FRAXC) (McAvoy et al., 2007), is frequently 
targeted by gross deletions in patients with Duchenne 
and Becker muscular dystrophy (MIM 310200 and 
300376, respectively) and in those with various cancers 
(Mitsui et al., 2010). Recently, CNVs in the human  
genome have been identified in control subjects by 
various methodologies, including array CGH, single-
nucleotide polymorphism genotyping, and massively 
parallel sequencing (Kidd et al., 2008; Korbel et al., 
2007; Mills et al., 2011; Perry et al., 2006; Redon et al., 
2006; Sudmant et al., 2011). Because sample selection 
bias inevitably affects the distributions of germline 
rearrangements, unbiased knowledge about CNVs 
distributions in the human genome will also be required 
to determine whether a common mechanism can 
underlie CFSs. Such investigations will certainly be 
essential for a better understanding of the molecular 
basis of CFSs and human diseases associated with 
instabilities in the human genome. 
External Links 
The NCBI Database of Genomic Structural Variation  
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(dbVAR) accession number for the breakpoint 
positions reported in this paper is nstd36. 
http://www.ncbi.nlm.nih.gov/dbvar/studies/nstd36/. 
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